Cord blood transplant with chemo and radiation for high-risk blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Skin clinical trials.
This trial tests a cord blood transplant after a reduced-intensity chemotherapy and radiation regimen for patients with high-risk blood cancers like leukemia, lymphoma, or MDS. The goal is to see if this approach can help destroy cancer cells and restore healthy blood cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 months and 65 years old.
- You have a high-risk blood cancer such as acute leukemia, chronic myeloid leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma, or blastic plasmacytoid dendritic cell neoplasm.
- Your cancer is in remission or has low levels of blasts (immature cells) in the bone marrow or blood.
- Your heart, kidney, liver, and lung function are within trial limits.
- You have not had more than one prior stem cell transplant or any prior allogeneic transplant.
- You do not have active infections, HIV, or central nervous system involvement of your cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
This study tests whether using cord blood stem cells (collected from umbilical cords after birth) can help treat high-risk blood cancers in children and young adults when a matched donor is not quickly available. Cord blood transplants may help prevent cancer from coming back.
This trial tests whether adding extra white blood cells (granulocytes) to a cord blood transplant can improve outcomes for people with poor-risk leukemia. It's for patients aged 16 to 55 who have certain genetic mutations or not fully responding to chemotherapy.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
Hear when a new Acute Leukemia of Ambiguous Lineage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.